BDX

— Fundamental Stock Analysis and Report Card

Healthcare : Medical - Instruments & Supplies

Located in Franklin Lakes, NJ, US. Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.

Growth

Revenue, earnings and profitability.

Strong revenue growth and earnings can attract investors, driving the stock price up. Profitability indicates the company's efficiency and sustainability, which impacts investor confidence. Poor performance in these areas can lead to a decrease in stock price.

Revenue History

Earnings History

Margins

Gross Margin TTM
46.48%
EBITDA Margin TTM
21.92%
Net Margin TTM
5.33%
Earnings Per Share TTM
4.06
Statements

Income & Cash Flow analysis.

An income statement shows what a company earned and spent over a period — revenue at the top, costs and expenses in between, and net income at the bottom. A cash flow statement tracks the actual cash moving in and out, across operations, investing, and financing. Read together, they show whether reported earnings are backed by real cash.

Becton, Dickinson and Company
Select Period:
Q2 2026
Total ($)
Q2 2026
Margin (%)
Revenue
4.7b
-558.0m
-10.6%
Gross Income
2.2b
-103.0m
-4.6%
46%
+2.9pp
+6.7%
EBITDA
709.0m
-413.0m
-36.8%
15%
-6.2pp
-29.3%
Operating Income
94.0m
-452.0m
-82.8%
2%
-8.4pp
-80.7%
Net Income
-311.0m
-619.0m
-201.0%
-7%
-12.4pp
-212.9%
Earnings Per Share
-1.11
-2.2
-203.7%
Operating Cash Flow
671.0m
+507.0m
+309.1%
14%
+11.1pp
+357.6%
Free Cash Flow
546.0m
+511.0m
+1.5k%
12%
+10.9pp
+1.6k%
Research & Development
249.0m
-53.0m
-17.5%
5%
-0.4pp
-7.8%